Regional delivery of oncolytic vaccinia virus: it's time for clinical trials.
作者信息
Downs-Canner Stephanie, Bartlett David L
机构信息
Division of Surgical Oncology, University of Pittsburgh, Pittsburgh, PA, USA.
出版信息
Ann Surg Oncol. 2014 Jul;21(7):2127-8. doi: 10.1245/s10434-014-3660-3. Epub 2014 Mar 28.
Abstract
摘要
相似文献
1
Regional delivery of oncolytic vaccinia virus: it's time for clinical trials.
Ann Surg Oncol. 2014 Jul;21(7):2127-8. doi: 10.1245/s10434-014-3660-3. Epub 2014 Mar 28.
2
Oncolytic vaccinia virus as an adjuvant treatment to cytoreductive surgery for malignant peritoneal mesothelioma.
Ann Surg Oncol. 2014 Jul;21(7):2259-66. doi: 10.1245/s10434-014-3651-4. Epub 2014 Apr 10.
3
Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis.
Clin Cancer Res. 2018 Sep 15;24(18):4388-4398. doi: 10.1158/1078-0432.CCR-18-0244. Epub 2018 May 17.
4
Radiological predictors of complete cytoreduction in 59 patients with peritoneal mesothelioma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a UK referral centre.
Br J Radiol. 2017 Nov;90(1079):20170361. doi: 10.1259/bjr.20170361. Epub 2017 Aug 22.
5
ASO Author Reflections: Analysis of Treatment Strategies and Outcomes in Malignant Peritoneal Mesothelioma: Insights from a Multi-center Study.
Ann Surg Oncol. 2024 Sep;31(9):6276-6277. doi: 10.1245/s10434-024-15653-7. Epub 2024 Jun 25.
6
Treating peritoneal mesothelioma with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. A case series and review of the literature.
Int J Hyperthermia. 2015;31(8):850-6. doi: 10.3109/02656736.2015.1075071. Epub 2015 Sep 18.
7
A proposal of Brazilian Society of Surgical Oncology (BSSO/SBCO) for standardizing cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) procedures in Brazil: pseudomixoma peritonei, appendiceal tumors and malignant peritoneal mesothelioma.
Rev Col Bras Cir. 2017 Sep-Oct;44(5):530-544. doi: 10.1590/0100-69912017005016.
8
Peritoneal Metastases from Malignant Mesothelioma.
Surg Oncol Clin N Am. 2018 Jul;27(3):539-549. doi: 10.1016/j.soc.2018.02.010.
9
10
Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
BMJ Open. 2019 May 14;9(5):e026779. doi: 10.1136/bmjopen-2018-026779.
本文引用的文献
1
Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis.
Ann Surg Oncol. 2014 Apr;21(4):1159-65. doi: 10.1245/s10434-013-3358-y. Epub 2013 Dec 10.
2
An oncolytic vaccinia virus expressing the human sodium iodine symporter prolongs survival and facilitates SPECT/CT imaging in an orthotopic model of malignant pleural mesothelioma.
Surgery. 2013 Sep;154(3):486-95. doi: 10.1016/j.surg.2013.06.004. Epub 2013 Jul 23.
3
A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer.
Gynecol Oncol. 2013 Sep;130(3):518-24. doi: 10.1016/j.ygyno.2013.06.003. Epub 2013 Jun 10.
4
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.
Nat Med. 2013 Mar;19(3):329-36. doi: 10.1038/nm.3089. Epub 2013 Feb 10.
5
A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases.
Clin Cancer Res. 2010 Nov 1;16(21):5277-87. doi: 10.1158/1078-0432.CCR-10-0791. Epub 2010 Oct 26.
6
Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.
Cancer Res. 2010 Feb 1;70(3):875-82. doi: 10.1158/0008-5472.CAN-09-2762. Epub 2010 Jan 26.
7
Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response.
Cancer Res. 2008 Jun 15;68(12):4882-92. doi: 10.1158/0008-5472.CAN-07-6265.
8
Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses.
J Thorac Oncol. 2006 Sep;1(7):701-11. doi: 10.1097/01243894-200609000-00017.
9
Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer.
J Clin Oncol. 2002 Mar 15;20(6):1562-9. doi: 10.1200/JCO.2002.20.6.1562.
10
Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.
Cancer Res. 2001 Dec 15;61(24):8751-7.
Zotero 插件